Open-label Study of Surufatinib in Japanese Patients
- Conditions
- Neuroendocrine TumorsNon-hematologic Malignancy
- Interventions
- Registration Number
- NCT05077384
- Lead Sponsor
- Hutchmed
- Brief Summary
This is a phase 1/2, open-label, multi-centre study of surufatinib in patients with unresectable, locally advanced, or recurrent nonhematologic malignancies who do not respond or are intolerant to standard of care.
- Detailed Description
The purpose of this study is to evaluate the tolerability and efficacy of surufatinib in Japanese patients.
The study will be conducted in 2 parts:
* Part 1 - evaluation of tolerability and safety of surufatinib and confirmation of the recommended clinical dose in Japanese patients with nonhematologic malignancies
* Part 2 - evaluation of antitumor activity and confirmation of tolerability of surufatinib in Japanese patients with NETs
All patients will be treated with oral surufatinib 300 mg QD in treatment cycles of 28 days starting on Cycle 1 Day 1.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 36
-
Histologically or cytologically documented disease as follows:
- Part 1: unresectable, locally advanced or metastatic nonhematologic malignancy that is relapsed/refractory to or intolerant of established therapies known to provide clinical benefit
- Part 2: locally advanced or metastatic, low (grade 1) or intermediate (grade 2) grade NETs that have been previously treated with at least 1 line of systemic therapy
-
Has radiologic evidence of progressive tumour within 12 months of study enrolment
-
Is willing and able to provide informed consent
-
Is ≥20 years of age
-
Has measurable lesions according to RECIST Version 1.1
-
Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
-
Female patients of childbearing potential and male patients with partners of childbearing potential agree to use a highly effective form(s) of contraception
Key
- Women who are pregnant and lactating, or possibly pregnant.
- Has a history of interstitial lung disease (ILD)/noninfectious pneumonitis, has current ILD/pneumonitis, or has suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
- Known active viral hepatits
- Has an AE due to previous anti-tumour therapy that has not recovered to ≤CTCAE Grade 1, except alopecia and peripheral neurotoxicity with ≤CTCAE Grade 2 caused by platinum chemotherapy
- Uncontrollable hypertension, defined as systolic blood pressure ≥140 mmHg and/or diastolic blood pressure ≥90 mmHg, despite antihypertensive medication
- Gastrointestinal disease or condition within 6 months prior to first dose
- Has a history or presence of a serious haemorrhage (>30 mL within 3 months) or haemoptysis (>5 mL blood within 4 weeks)
- Clinically significant cardiovascular disease.
- Brain metastases and/or spinal cord compression untreated with surgery and/or radiotherapy, and without clinical imaging evidence of stable disease (SD) for 14 days or longer; patients requiring steroids within 4 weeks prior to start of study treatment will be excluded.
- A high risk of bleeding at screening due to tumour invasion into major vessels, such as pulmonary artery, the superior vena cava, or the inferior vena cava, as determined by investigators.
- Has arterial thrombosis or deep venous thrombosis within 6 months prior to first dosing, or thromboembolic events (including stroke and/or transient ischaemic attack) within 12 months prior to first dosing.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Surufatinib Surufatinib Oral surufatinib 300 mg once daily in treatment cycles of 28 days starting at Cycle 1 Day1
- Primary Outcome Measures
Name Time Method Part 1: Incidence of treatment-emergent adverse events (TEAEs) graded by the Investigator according to National Cancer Institute Common Terminology Criteria for Adverse Events Version 5.0 (NCI-CTCAE v5.0). Up to 2 years To evaluate surufatinib-related adverse events in patients with NETs
Part 2: Objective response rate. This will be assessed on the proportion of participants with partial response or complete response as determined by the Investigator based on RECIST v1.1 Up to 2 years The primary outcome of part 2 will be objective response rate in patients with NETs when treated with surufatinib
- Secondary Outcome Measures
Name Time Method Progression Free Survival (PFS) which is defined as the time from randomization to the first occurrence of disease progression as determined by the investigator based on RECIST v1.1, or death from any cause, whichever occurs first Up to 2 years The duration between the enrollment date and the first disease progression (PD) or death (whichever comes first).
Duration of Response (DOR) which will be defined as the time from the first response to disease progression documented after treatment initiation or death, whichever occurs first. DOR will include CR, CR plus CRi, overall response (OR), and CR plus CRh. Up to 2 years The duration between the date the criteria for complete response or partial response was first measured (first record shall prevail) and the date of disease recurrence or progression as objectively recorded
Observed plasma concentrations of surufatinib which will be assessed by the Cmax, tmax, AUC, Cmin and CL/F Up to 2 years Blood sampling will be taken to measure levels of the study drug
Trial Locations
- Locations (12)
Kagawa University Hospital
🇯🇵Kagawa, Japan
Tohoku University Hospital
🇯🇵Sendai, Japan
Kyushu University Hospital
🇯🇵Fukuoka, Japan
Fukuoka Sanno Hospital
🇯🇵Fukuoka, Japan
National Cancer Centre Hospital East
🇯🇵Kashiwa-shi, Japan
Kyorin University Hospital
🇯🇵Mitaka, Japan
Kansia Electric Power Hospital
🇯🇵Osaka, Japan
Kyoto University Hospital
🇯🇵Kyoto, Japan
Aichi Cancer Centre
🇯🇵Nagoya, Japan
Hokkaido University Hospital
🇯🇵Sapporo, Japan
National Cancer Centre Hospital
🇯🇵Tokyo, Japan
Yokohama City University Hospital
🇯🇵Yokohama, Japan